Story perspectives

Eli Lilly Expands Access to Retatrutide, Shows 22% Loss

8/4/2026

Summary

Story summary

Eli Lilly announced an expanded-access program allowing patients to apply for retatrutide before FDA approval.
Lilly requires age 18+, obesity with two complications, inability to join a trial, and is reviewing provider requests.
STAT reported the first special-access case, a 79-year-old patient receiving retatrutide outside a trial.
An 80-week trial showed 22.6 % weight loss at the highest dose.
Lilly will file an FDA application for retatrutide in Q1 next year.

1 of 1

Story summary

Eli Lilly announced an expanded-access program allowing patients to apply for retatrutide before FDA approval.
Lilly requires age 18+, obesity with two complications, inability to join a trial, and is reviewing provider requests.
STAT reported the first special-access case, a 79-year-old patient receiving retatrutide outside a trial.
An 80-week trial showed 22.6 % weight loss at the highest dose.
Lilly will file an FDA application for retatrutide in Q1 next year.